Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Blueprint

Tech millionaire’s reasonable explanation for why he spends $2m a year to be 18 again

Why would a 45-year-old father-of-three want to be 18 again? Chelsea Ritschel speaks to Bryan Johnson about his controversial quest to find the fountain of youth

The Independent UK

BrewDog loses B Corp status

Certificate taken away following accusations and investigations around treatment of current and former staff

Insider UK

Which generation will be the biggest winners of Supercars' Gen3 shake-up?

The shift to new Gen3 cars that provide less downforce in 2023 is set to pose a significant challenge to teams and drivers in Supercars. But will series veterans or the paddock's young guns adapt best to the changes?

Motorsport

From analysis to the latest developments in health,
read the most diverse news in one place.

Which generation will be the biggest winners of Supercars' Gen3 shakeup?

Autosport

Dan Rodricks: Wes Moore wants a year of paid public service for high school grads. Sounds good. Sounds costly

Democratic gubernatorial candidate Wes Moore has proposed a one-year public service option for young Marylanders who graduate from high school without a plan for college or the skills they need for a good job. His proposal for a “service year option” came up during a recent wide-ranging interview at The…

Tribune News Service

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint

Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Work to begin on 'gas-free' townhouses in Sneinton

'There isn’t another project like it in the city'

Nottingham Post

Patrick Quinn could make a run at Lori Lightfoot

Sneed: Bolstered by polling, former governor supported mayor last time

Chicago Sun-Times

Housing development update on 'highly sought' area next to River Trent

It covers a huge area

Nottingham Post

Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug

Investors Business Daily

From wrapping a Ferrari ahead of Monaco GP to a wheelbarrow, Nottingham business celebrates 35 years

Blueprint Nottingham is celebrating 35 years in business this year

Nottingham Post

After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer

Blueprint Medicines Corp (NASDAQ: BPMC)

Benzinga

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Nottingham City Council

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.